Some batches of Durisan hand sanitizer have been previously recalled and in a new update, the company has further expanded the recall. The U.S. Food and Drug Administration (FDA) explained that the move was due to the fact that the affected hand sanitizers were contaminated with a type of bacteria that could infect the users.
The expanded recall announcement
Based on the FDA’s recall notice that was posted on Tuesday, May 18, Durisan Sanit Technologies updated the recall for its anti-microbial hand sanitizer products. Now, the batches of products to be recalled were expanded to add those that were manufactured after April 10, 2019, and have not expired yet.
The company made the decision because the affected bottles were said to have been contaminated with common bacteria called Burkholderia contaminans. People infected may not experience reactions but for others, they may suffer from more serious effects once the bacteria enter their bloodstream through scrapes or wounds after using the hand sanitizer.
An infection could result from this, as per the FDA. The agency also warned that people with weaker immune systems are more susceptible to infection so the use of the contaminated hand sanitizer is risky.
Other information of the recalled lots
Fox Business mentioned that as per the Centers for Disease Control and Prevention (CDC), Burkholderia cepacia is found in water and soil. This bacteria may also be a little complicated to treat because it is said to be usually resistant to common antibiotics.
In any case, the recalled Durisan hand sanitizer includes 47 lots of the products. These covered the ones packed in various bottle sizes of 18 ml credit cards, 118 ml, 236 ml, 300 ml and 500 ml. The wall-mounted dispensers that use 1000 ml bottles are also included.
Fortunately, there is no report of adverse reactions yet or complaints from customers regarding the contaminated Durisan hand sanitizer. With the voluntary recall of its maker, the FDA said that distributors and retailers were already notified too.
“Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using this drug product,” the FDA wrote in the expanded recall announcement. “Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.”


Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry
Australia’s Economic Growth Slows in Q3 Despite Strong Investment Activity
Dollar Slides to Five-Week Low as Asian Stocks Struggle and Markets Bet on Fed Rate Cut
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment
USPS Expands Electric Vehicle Fleet as Nationwide Transition Accelerates
Gold Prices Steady as Markets Await Key U.S. Data and Expected Fed Rate Cut
Europe Confronts Rising Competitive Pressure as China Accelerates Export-Led Growth
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO
Asia’s IPO Market Set for Strong Growth as China and India Drive Investor Diversification
RBI Cuts Repo Rate to 5.25% as Inflation Cools and Growth Outlook Strengthens
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand
Japan’s Nikkei Drops as Markets Await Key U.S. Inflation Data
Germany’s Economic Recovery Slows as Trade Tensions and Rising Costs Weigh on Growth
BOJ Faces Pressure for Clarity, but Neutral Rate Estimates Likely to Stay Vague
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 



